Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Opus Genetics, Inc. (IRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.17
1 Year Target Price $7.17
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.79% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 120.42M USD | Price to earnings Ratio - | 1Y Target Price 7.17 |
Price to earnings Ratio - | 1Y Target Price 7.17 | ||
Volume (30-day avg) 3 | Beta 0.37 | 52 Weeks Range 0.65 - 2.16 | Updated Date 10/17/2025 |
52 Weeks Range 0.65 - 2.16 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -309.02% |
Management Effectiveness
Return on Assets (TTM) -55.2% | Return on Equity (TTM) -200.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76405499 | Price to Sales(TTM) 7.81 |
Enterprise Value 76405499 | Price to Sales(TTM) 7.81 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA -2.55 | Shares Outstanding 59908055 | Shares Floating 27717061 |
Shares Outstanding 59908055 | Shares Floating 27717061 | ||
Percent Insiders 21.89 | Percent Institutions 27.76 |
Upturn AI SWOT
Opus Genetics, Inc.
Company Overview
History and Background
Opus Genetics, Inc. is a gene therapy company focused on developing treatments for inherited retinal diseases. Founded in 2020 as a spin-out from the University of Pennsylvania, it aims to translate cutting-edge research into novel therapies for patients with significant unmet needs. The company has rapidly advanced several preclinical programs targeting various forms of inherited blindness.
Core Business Areas
- Gene Therapy Development: Focuses on research and development of gene therapy candidates for inherited retinal diseases.
- Manufacturing: Develops and utilizes proprietary manufacturing processes for gene therapy vectors.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of gene therapy candidates.
Leadership and Structure
The leadership team comprises experienced executives in gene therapy and ophthalmology. The organizational structure is typical of a biotech startup, with functional departments focused on R&D, clinical development, manufacturing, and business operations.
Top Products and Market Share
Key Offerings
- OPH-101 (Leber Congenital Amaurosis (LCA) caused by mutations in the NMNAT1 gene): OPH-101 is Opus Genetics' lead candidate, a gene therapy for LCA caused by mutations in the NMNAT1 gene. There is currently no approved treatment for this specific form of LCA. Competitors include companies developing gene therapies for other forms of inherited retinal diseases. Due to the limited treatment options, market share information for this specific sub-type of LCA is immature, but presents a significant unmet medical need and potential market opportunity.
- OPH-102 (retinitis pigmentosa caused by mutations in the RHO gene): OPH-102 is a gene therapy candidate for retinitis pigmentosa caused by mutations in the RHO gene. This targets a different mutation of retinal disease. Competitors include companies developing gene therapies for other forms of inherited retinal diseases. Due to the limited treatment options, market share information for this specific sub-type of retinitis pigmentosa is immature, but presents a significant unmet medical need and potential market opportunity.
Market Dynamics
Industry Overview
The gene therapy market is experiencing significant growth, driven by advancements in vector technology and increasing regulatory acceptance. The inherited retinal disease segment is a promising area within gene therapy, with several therapies already approved and many more in development.
Positioning
Opus Genetics is positioned as a specialized gene therapy company focused on inherited retinal diseases with few or no treatment options. Its competitive advantage lies in its focus on specific genetic mutations and its experienced leadership team.
Total Addressable Market (TAM)
The total addressable market for gene therapies treating inherited retinal diseases is estimated to be in the billions of dollars annually. Opus Genetics' position is to capture a significant portion of this TAM by focusing on specific genetic mutations with large patient populations and limited treatment options.
Upturn SWOT Analysis
Strengths
- Strong scientific foundation based on research from the University of Pennsylvania
- Experienced leadership team with expertise in gene therapy and ophthalmology
- Focus on specific genetic mutations with high unmet needs
- Proprietary manufacturing processes
- Strong financial backing from venture capital investors
Weaknesses
- Early-stage company with limited clinical data
- Reliance on successful clinical trial outcomes
- High capital requirements for gene therapy development
- Competition from larger, more established gene therapy companies
Opportunities
- Potential for breakthrough therapies for inherited retinal diseases
- Expansion into other genetic eye diseases
- Strategic partnerships with pharmaceutical companies
- Accelerated regulatory pathways for orphan diseases
- Increasing awareness and acceptance of gene therapy
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other gene therapy companies
- High manufacturing costs
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- Spark Therapeutics (Roch) (ROG.SW)
- AGTC (AGTC)
- MeiraGTx (MGTX)
Competitive Landscape
Opus Genetics is a smaller player in the gene therapy space compared to Spark Therapeutics. However, its focus on specific genetic mutations and strong scientific foundation give it a competitive advantage in certain niche markets.
Growth Trajectory and Initiatives
Historical Growth: Opus Genetics has experienced rapid growth since its founding, fueled by venture capital investment and progress in preclinical development.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analysts predict significant growth potential if its lead candidate, OPH-101, is approved.
Recent Initiatives: Focus on advancing OPH-101 and OPH-102 through clinical trials, expanding its pipeline of gene therapy candidates, and building its manufacturing capabilities.
Summary
Opus Genetics is a promising gene therapy company focused on inherited retinal diseases. Its strong scientific foundation and experienced leadership team are key strengths. Success hinges on clinical trial outcomes and effective commercialization. Opus must navigate regulatory hurdles and competition to achieve its growth potential. The lead product is still in development phases and will make up most of the company's evaluation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Opus Genetics website
- Company press releases
- Industry reports
- SEC Filings for Public Comparables (Spark, AGTC, MeiraGTx)
- Venture Capital Databases
Disclaimers:
This analysis is based on publicly available information and analyst estimates. The gene therapy market is rapidly evolving, and actual results may differ materially from these projections. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opus Genetics, Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2005-05-23 | CEO & Director Mr. George Magrath M.B.A., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://opusgtx.com |
Full time employees 18 | Website https://opusgtx.com | ||
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.